EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Recent Progress in Urea‐Containing Compounds as Tyrosine Kinase Inhibitors

Farid M Sroor iD

Chemistry & Biodiversity · 2026

DOI: 10.1002/cbdv.71562 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Farid M Sroor. Beteiligte Einrichtung: Organometallic and Organometalloid Chemistry Department, National Research Centre, Cairo, 12622, Egypt. Hauptthemen laut MEDLINE: Urea, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 138 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains one of the leading causes of mortality worldwide. Dysregulated cellular signaling pathways play a pivotal role in tumorigenesis, tumor progression, and metastasis. Among these, tyrosine kinases (TKs) constitute a critical class of enzymes that catalyze the phosphorylation of tyrosine residues on target proteins, thereby regulating key cellular processes including growth, differentiation, and survival. TKs have revolutionized cancer therapy by selectively targeting these enzymes, resulting in suppressed tumor growth and improved clinical outcomes for patients. Urea‐containing motifs represent one of the most important bioactive functional groups in medicinal chemistry. In particular, unsymmetrical alkyl‐ and benzylureas are widely employed as key structural components in numerous approved drugs. This structural feature enables versatile modifications that enhance physicochemical properties, including solubility, metabolic stability, and bioavailability. This review explores the current landscape of antineoplastic urea‐based tyrosine kinase inhibitors, presenting an exhaustive examination of contemporary urea‐containing compounds that inhibit TKs while elucidating their mechanisms of action and molecular targets. In recent years, computational technologies have become indispensable in modern drug discovery. They significantly accelerate the identification of new TKIs and support the repurposing of established pharmaceuticals. Ultimately, the review addresses the prevailing challenges and future opportunities in the advancement of urea‐containing tyrosine kinase inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UreaProtein Kinase InhibitorsAntineoplastic AgentsHumansProtein-Tyrosine KinasesNeoplasmsAnimalsStructure-Activity RelationshipMolecular StructureTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

FGFRVEGFRanti‐cancerdrug designstructure–activity relationshiptyrosine kinase inhibitorsurea derivatives

Substanzen

UreaProtein Kinase InhibitorsProtein-Tyrosine KinasesAntineoplastic AgentsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Organometallic and Organometalloid Chemistry Department, National Research Centre, Cairo, 12622, Egypt.

ORCID-Profile: Farid M Sroor

Zitieren

APA

Sroor, F. M. (2026). Recent Progress in Urea‐Containing Compounds as Tyrosine Kinase Inhibitors. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.71562

Vancouver

Sroor FM. Recent Progress in Urea‐Containing Compounds as Tyrosine Kinase Inhibitors. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.71562

BibTeX
@article{Sroor2026,
  author = {Sroor, Farid M},
  title = {Recent Progress in Urea‐Containing Compounds as Tyrosine Kinase Inhibitors},
  journal = {Chemistry & Biodiversity},
  year = {2026},
  doi = {10.1002/cbdv.71562}
}
Kostenlos starten →